Chimerix (NASDAQ:CMRX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Chimerix (NASDAQ:CMRX) in a report published on Sunday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other brokerages have also weighed in on CMRX. Jefferies Financial Group reaffirmed a “hold” rating and issued a $8.50 target price (down from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th. Wedbush restated a “neutral” rating and issued a $8.55 price objective (up from $7.00) on shares of Chimerix in a report on Wednesday, March 5th. Finally, HC Wainwright reiterated a “neutral” rating and set a $8.55 target price (down previously from $11.00) on shares of Chimerix in a report on Wednesday, March 5th.

Chimerix Price Performance

Shares of CMRX stock opened at $8.51 on Friday. The firm’s 50-day simple moving average is $5.55 and its 200-day simple moving average is $2.96. Chimerix has a 1-year low of $0.75 and a 1-year high of $8.53. The firm has a market cap of $765.36 million, a P/E ratio of -9.05 and a beta of 0.32.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. The company had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.31 million. Analysts expect that Chimerix will post -0.99 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Michael T. Andriole sold 7,370 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the sale, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In the last three months, insiders sold 20,760 shares of company stock valued at $91,175. Company insiders own 13.10% of the company’s stock.

Hedge Funds Weigh In On Chimerix

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bender Robert & Associates purchased a new stake in shares of Chimerix during the fourth quarter valued at approximately $37,000. Susquehanna Fundamental Investments LLC acquired a new stake in Chimerix during the 4th quarter valued at $59,000. Jane Street Group LLC purchased a new stake in Chimerix during the 4th quarter worth $62,000. Diadema Partners LP acquired a new position in Chimerix in the 4th quarter worth $101,000. Finally, Squarepoint Ops LLC purchased a new position in Chimerix in the 4th quarter valued at about $130,000. Hedge funds and other institutional investors own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.